Piper Sandler Reaffirms Their Buy Rating on NovoCure (NVCR)
Piper Sandler analyst Jason Bednar maintained a Buy rating on NovoCure (NVCR – Research Report) today and set a price target of $28.00.
NovoCure’s Growth Potential Boosted by FDA Approval and Market Expansion
Leerink Partners analyst Jonathan Chang maintained a Buy rating on NovoCure (NVCR – Research Report) yesterday and set a price target of ...
Buy Rating Affirmed for NovoCure as FDA Approval Expands Optune’s Market Potential
Larry Biegelsen, an analyst from Wells Fargo, maintained the Buy rating on NovoCure (NVCR – Research Report). The associated price target ...
NovoCure’s Optune Lua Gains FDA Approval for NSCLC, Projecting Significant Sales Growth and Expansion
H.C. Wainwright analyst Emily Bodnar upgraded the rating on NovoCure (NVCR – Research Report) to a Buy today, setting a price target of ...
Yahoo Finance2d
NovoCure Limited (NVCR)
As of 9:38 AM EDT. Market Open.